相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Developing an effective treatment algorithm for rheumatoid arthritis
Edward C. Keystone et al.
RHEUMATOLOGY (2012)
Kinase inhibitors: a new class of antirheumatic drugs
Vasileios C. Kyttaris
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ARTHRITIS AND RHEUMATISM (2011)
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
J. L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi et al.
NATURE IMMUNOLOGY (2009)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment
J. G. Walker et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis
JG Walker et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
分享论文
